Tags

Type your tag names separated by a space and hit enter

Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies.
J Peripher Nerv Syst. 2018 12; 23(4):227-234.JP

Abstract

Antibodies to the ganglioside GD1b have been reported in various forms of immune-mediated neuropathy, but their clinical relevance for diagnosis and prognosis is unknown. We investigated the prevalence of anti-GD1b antibodies in acute and chronic immune-mediated neuropathies, and the clinical presentation and outcome in Guillain-Barré syndrome (GBS) and Miller Fisher-GBS overlap syndrome (MF-GBS). Anti-GD1b, anti-GM1 and anti-GQ1b antibodies were tested in serum of patients with GBS (N = 165), Miller Fisher syndrome (N = 10), MF-GBS (N = 28), monoclonal gammopathy of unknown significance neuropathy (MGUS; N = 101), chronic inflammatory demyelinating polyneuropathy (N = 29), paraneoplastic syndrome with anti-Hu-associated neuropathy (PNS; N = 11), other auto-immune diseases (AID; N = 60), and healthy controls (HC; N = 60). All samples were tested by enzyme-linked immunosorbent assay according to the Inflammatory Neuropathy Cause and Treatment protocol. IgM anti-GD1b antibodies were found in GBS (N = 4; 2.4%), MGUS (N = 3; 3.0%), and PNS patients (N = 1; 9.1%). IgG anti-GD1b antibodies were found in GBS (N = 20; 12.1%) and MF-GBS (N = 4; 14.3%) patients, but not in the AID and HC group. In the combined group of MF-GBS and GBS patients ((MF-)GBS), 14/36 (38.9%) patients with IgG anti-GD1b antibodies also had IgG anti-GM1 antibodies, and IgG anti-GD1b and IgG anti-GQ1b antibodies were found in 3/29 (10.3%) patients. Patients with (MF-)GBS and anti-GD1b without anti-GM1 antibodies did not differ regarding sensory disturbances or disease severity but recovered faster regarding the ability to walk independently compared with patients without anti-GD1b antibodies (P = 0.031) and with patients with both anti-GD1b and anti-GM1 antibodies (P = 0.034). In conclusion, testing for anti-GD1b antibodies may identify a specific group of immune-mediated neuropathies and (MF-)GBS patients with only anti-GD1b antibodies tend to recover faster.

Authors+Show Affiliations

Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands.Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30101437

Citation

Taams, Noor E., et al. "Clinical Relevance of Serum Antibodies to GD1b in Immune-mediated Neuropathies." Journal of the Peripheral Nervous System : JPNS, vol. 23, no. 4, 2018, pp. 227-234.
Taams NE, Notermans NC, Fokkink WR, et al. Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies. J Peripher Nerv Syst. 2018;23(4):227-234.
Taams, N. E., Notermans, N. C., Fokkink, W. R., Tio-Gillen, A. P., Huizinga, R., Schreurs, M. W. J., & Jacobs, B. C. (2018). Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies. Journal of the Peripheral Nervous System : JPNS, 23(4), 227-234. https://doi.org/10.1111/jns.12285
Taams NE, et al. Clinical Relevance of Serum Antibodies to GD1b in Immune-mediated Neuropathies. J Peripher Nerv Syst. 2018;23(4):227-234. PubMed PMID: 30101437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies. AU - Taams,Noor E, AU - Notermans,Nicolette C, AU - Fokkink,Willem-Jan R, AU - Tio-Gillen,Anne P, AU - Huizinga,Ruth, AU - Schreurs,Marco W J, AU - Jacobs,Bart C, Y1 - 2018/09/12/ PY - 2018/07/02/received PY - 2018/08/08/revised PY - 2018/08/08/accepted PY - 2018/8/14/pubmed PY - 2019/10/23/medline PY - 2018/8/14/entrez KW - Guillain-Barré syndrome KW - anti-GD1b antibodies KW - immune-mediated neuropathy KW - prognosis KW - sensory neuropathy SP - 227 EP - 234 JF - Journal of the peripheral nervous system : JPNS JO - J. Peripher. Nerv. Syst. VL - 23 IS - 4 N2 - Antibodies to the ganglioside GD1b have been reported in various forms of immune-mediated neuropathy, but their clinical relevance for diagnosis and prognosis is unknown. We investigated the prevalence of anti-GD1b antibodies in acute and chronic immune-mediated neuropathies, and the clinical presentation and outcome in Guillain-Barré syndrome (GBS) and Miller Fisher-GBS overlap syndrome (MF-GBS). Anti-GD1b, anti-GM1 and anti-GQ1b antibodies were tested in serum of patients with GBS (N = 165), Miller Fisher syndrome (N = 10), MF-GBS (N = 28), monoclonal gammopathy of unknown significance neuropathy (MGUS; N = 101), chronic inflammatory demyelinating polyneuropathy (N = 29), paraneoplastic syndrome with anti-Hu-associated neuropathy (PNS; N = 11), other auto-immune diseases (AID; N = 60), and healthy controls (HC; N = 60). All samples were tested by enzyme-linked immunosorbent assay according to the Inflammatory Neuropathy Cause and Treatment protocol. IgM anti-GD1b antibodies were found in GBS (N = 4; 2.4%), MGUS (N = 3; 3.0%), and PNS patients (N = 1; 9.1%). IgG anti-GD1b antibodies were found in GBS (N = 20; 12.1%) and MF-GBS (N = 4; 14.3%) patients, but not in the AID and HC group. In the combined group of MF-GBS and GBS patients ((MF-)GBS), 14/36 (38.9%) patients with IgG anti-GD1b antibodies also had IgG anti-GM1 antibodies, and IgG anti-GD1b and IgG anti-GQ1b antibodies were found in 3/29 (10.3%) patients. Patients with (MF-)GBS and anti-GD1b without anti-GM1 antibodies did not differ regarding sensory disturbances or disease severity but recovered faster regarding the ability to walk independently compared with patients without anti-GD1b antibodies (P = 0.031) and with patients with both anti-GD1b and anti-GM1 antibodies (P = 0.034). In conclusion, testing for anti-GD1b antibodies may identify a specific group of immune-mediated neuropathies and (MF-)GBS patients with only anti-GD1b antibodies tend to recover faster. SN - 1529-8027 UR - https://www.unboundmedicine.com/medline/citation/30101437/Clinical_relevance_of_serum_antibodies_to_GD1b_in_immune_mediated_neuropathies_ L2 - https://doi.org/10.1111/jns.12285 DB - PRIME DP - Unbound Medicine ER -